Citation Impact
20 standout
Citing Papers
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
2024 Standout
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Works of Johan Pluvy being referenced
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
2019
Author Peers
| Author | PRM | Oncology | Epidemiology | Cancer Research | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Johan Pluvy | 112 | 129 | 13 | 44 | 14 | 168 | |
| Jessica Lindlau | 8 | 331 | |||||
| A. Filipovic | 6 | 11 | 372 | ||||
| Douglas C. McFarland | 14 | 22 | 68 | 109 | 92 | 2.1k | |
| Nikhil Patankar | 1 | 1 | 4 | 5 | 10 | ||
| Ping Zhao | 1 | 19 | 194 |
All Works
Login with ORCID to disown or claim papers
Loading papers...